AstraZeneca showcases new data from the SERENA-6 data of camizestrant in breast cancer that it hopes will get FDA’s review of the drug back on track.
Abivax slides on phase 3 data in ulcerative colitis
Shares in Abivax have tumbled after it announced phase 3 data with ulcerative colitis drug obefazimod that included several cases of cancer.

